| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-77913-25ug | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-64895SS | |||
| Azide and BSA Free | NBP2-80651 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-77758-0.5mg | |||
| BSA Free | NB100-77758SS | |||
| Azide and BSA Free | NBP2-80627 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB300-514SS | |||
| Azide and BSA Free | NBP2-80785 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-78039SS | |||
| Azide and BSA Free | NBP2-80921 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-54790SS | |||
| Azide and BSA Free | NBP2-80644 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-19775SS | |||
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Allophycocyanin | NB7446APC | |||
| Biotin | NB7446B | |||
| DyLight 350 | NB7446UV | |||
| DyLight 405 | NB7446V | |||
| DyLight 488 | NB7446G | |||
| DyLight 550 | NB7446R | |||
| DyLight 594 | NB7446DL594 | |||
| DyLight 650 | NB7446C | |||
| DyLight 680 | NB7446FR | |||
| DyLight 755 | NB7446IR | |||
| FITC | NB7448 | |||
| HRP | NB7449 | |||
| Janelia Fluor 525 | NB7446JF525 | |||
| Janelia Fluor 669 | NB7446JF669 | |||
| PE | NB7446PE | |||
| PerCP | NB7446PCP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-43312-0.5mg | |||
| BSA Free | NBP1-43312-0.05mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB110-55376SS | |||
![Immunocytochemistry/Immunofluorescence: CD63 Antibody (MEM-259) [NB100-77913] - Human HeLa cells. ICC/IF image submitted by a verified customer review.](http://images.novusbio.com/fullsize/CD63-Antibody-MEM-259-Immunocytochemistry-Immunofluorescence-NB100-77913-img0015.jpg "Immunocytochemistry/Immunofluorescence: CD63 Antibody (MEM-259) [NB100-77913] - Human HeLa cells. ICC/IF image submitted by a verified customer review.")
![Western Blot: CD63 Antibody (MEM-259) [NB100-77913] - Immunoblot analysis of CD63, CD81, TSG101, and CD9 protein in LSC-Exo and MSC-Exo. Image collected and cropped by CiteAb from the following publication (nature.com/articles/s41467-020-14344-7), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CD63-Antibody-MEM-259-Western-Blot-NB100-77913-img0016.jpg)
![Immunohistochemistry-Paraffin: CD63 Antibody (MEM-259) [NB100-77913] - Staining of human spleen (paraffin sections) using anti-CD63 (MEM-259).](http://images.novusbio.com/fullsize/CD63-Antibody-MEM-259-Immunohistochemistry-Paraffin-NB100-77913-img0018.jpg)
![Flow Cytometry: CD63 Antibody (MEM-259) [NB100-77913] - Flow Cytometry: CD63 Antibody (MEM-259) [FITC] [NB500-483] - Analysis of IgE-activated peripheral blood stained with anti-human CD63 (MEM-259) PE-CyTM5. Image using the FITC form of this antibody.](http://images.novusbio.com/fullsize/CD63-Antibody-MEM-259-Flow-Cytometry-NB100-77913-img0014.jpg)
![Immunocytochemistry/Immunofluorescence: CD63 Antibody (MEM-259) [NB100-77913] - Staining of human skin fibroblasts with anti-CD63 (MEM-259; green) after co-incubation of living cells with human Transferrin - Dyomics 547 (red); cell nuclei stained with DAPI (blue).](http://images.novusbio.com/fullsize/CD63-Antibody-MEM-259-Immunocytochemistry-Immunofluorescence-NB100-77913-img0001.jpg)
![Immunocytochemistry/Immunofluorescence: CD63 Antibody (MEM-259) [NB100-77913] - Staining of CD63 in human primary fibroblasts using anti-CD63 (MEM-259; green). Actin cytoskeleton was decorated by phalloidin (red) and cell nuclei stained with DAPI (blue).](http://images.novusbio.com/fullsize/CD63-Antibody-MEM-259-Immunocytochemistry-Immunofluorescence-NB100-77913-img0002.jpg)
![Immunocytochemistry/Immunofluorescence: CD63 Antibody (MEM-259) [NB100-77913] - Staining of CD63 in human HeLa cell line using anti-CD63 (MEM-259; green). Actin cytoskeleton was decorated by phalloidin (red) and cell nuclei stained with DAPI (blue).](http://images.novusbio.com/fullsize/CD63-Antibody-MEM-259-Immunocytochemistry-Immunofluorescence-NB100-77913-img0003.jpg)
![Flow Cytometry: CD63 Antibody (MEM-259) [NB100-77913] - Analysis using the FITC conjugate of NB100-77913. Staining of peripheral blood lymphocytes from a patient with allergy to bee venom after stimulation with bee venom, stained with anti-human CD63 (MEM-259) FITC.](http://images.novusbio.com/fullsize/CD63-Antibody-MEM-259-Flow-Cytometry-NB100-77913-img0006.jpg)
![Flow Cytometry: CD63 Antibody (MEM-259) [NB100-77913] - Analysis of IgE-activated peripheral blood stained with anti-human CD63 (MEM-259) PE.](http://images.novusbio.com/fullsize/CD63-Antibody-MEM-259-Flow-Cytometry-NB100-77913-img0009.jpg)
![Flow Cytometry: CD63 Antibody (MEM-259) [NB100-77913] - Analysis of IgE-activated peripheral blood stained with anti-human CD63 (MEM-259) purified, GAM-APC.](http://images.novusbio.com/fullsize/CD63-Antibody-MEM-259-Flow-Cytometry-NB100-77913-img0010.jpg)
![Flow Cytometry: CD63 Antibody (MEM-259) [NB100-77913] - Analysis of IgE-activated peripheral blood stained with anti-human CD63 (MEM-259) PerCP-CyTM5.5.](http://images.novusbio.com/fullsize/CD63-Antibody-MEM-259-Flow-Cytometry-NB100-77913-img0011.jpg)
![Flow Cytometry: CD63 Antibody (MEM-259) [NB100-77913] - Analysis of IgE-activated peripheral blood stained with anti-human CD63 (MEM-259) PerCP.](http://images.novusbio.com/fullsize/CD63-Antibody-MEM-259-Flow-Cytometry-NB100-77913-img0012.jpg)
![Flow Cytometry: CD63 Antibody (MEM-259) [NB100-77913] - Flow Cytometry: CD63 Antibody (MEM-259) [FITC] [NB500-483] - Analysis of IgE-activated peripheral blood stained with anti-human CD63 (MEM-259) Alexa Fluor® 488. Image using the FITC form of this antibody.](http://images.novusbio.com/fullsize/CD63-Antibody-MEM-259-Flow-Cytometry-NB100-77913-img0013.jpg)
![Western Blot: CD63 Antibody (MEM-259) - BSA Free [NB100-77913] - Cytokine & checkpoint molecule arrays from plasma exosomes showed a decreased concentration of IFN-gamma , IL-10, IL-13, B7-1, B7-2, & ICOSL in GBM patients in comparison to normal donors. (A) Quantification of IFN-gamma , IL-10, & IL-13 in plasma exosomes from normal donors & grade 4 GBM patients' plasma exosomes (mean ± SEM, n = 4/group, *P < 0.05). (B) Quantification of B7-1, B7-2, & ICOSL in plasma exosomes from normal donors & grade 4 GBM patients' plasma exosomes (mean ± SEM, n = 4/group). (C) Quantification of the immunosuppressive checkpoint & T cell costimulatory homolog protein PD-L1 in plasma exosomes from normal donors & grade 4 GBM patients' plasma exosomes (mean ± SEM, n = 4/group). Interestingly, PD-L1 is found at similar levels in both normal donor & glioma patient plasma exosomes & these findings were confirmed by western blot. Western Blot analysis also shows that exosomal markers Flotillin-1 & CD63 are found universally in plasma exosomes from normal donors (n = 3), glioblastoma (grade 4) patients (n = 4), & grade 3 glioma patients (n = 3), though CD63 expression may be slightly reduced in glioma patients. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31380286), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-77913_mouse-monoclonal-cd63-antibody-mem-259-310202415532072.jpg)
![Flow Cytometry: CD45 Antibody (OX-1) [NB100-64895] - Analysis using Alexa Fluor (R) 488 conjugate of CD45 antibody (OX-1). Rat Splenocytes were stained with CD45 antibody (OX-1) [NB100-64895] (blue) and a matched isotype control [NBP2-27287] (orange). Cells were incubated in an antibody dilution of 1 ug/mL for 20 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 488.](http://images.novusbio.com/fullsize/CD45-Antibody-OX-1-Flow-Cytometry-NB100-64895-img0005.jpg "Flow Cytometry: CD45 Antibody (OX-1) [NB100-64895] - Analysis using Alexa Fluor (R) 488 conjugate of CD45 antibody (OX-1). Rat Splenocytes were stained with CD45 antibody (OX-1) [NB100-64895] (blue) and a matched isotype control [NBP2-27287] (orange). Cells were incubated in an antibody dilution of 1 ug/mL for 20 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 488.")
![Flow Cytometry: CD45 Antibody (OX-1) [NB100-64895] - Analysis using the FITC conjugate of CD45 antibody (OX-1). Staining of rat spleen cells.](http://images.novusbio.com/fullsize/CD45-Antibody-OX-1-Flow-Cytometry-NB100-64895-img0004.jpg)
![Flow Cytometry: CD45 Antibody (OX-1) - BSA Free [NB100-64895] - Representative sequential gating during flow cytometry analysis of rat non-parenchymal liver cells (n = 4). Cells were labeled with antibodies to SE-1 (NB110-68095AF488), CD31, and CD45 (NB100-64895PE). LSECs were then identified as SE-1-Alexa488+ cells (e), and the biexponential CD45-PE/CD31-APC of events (f) were used to display and select the CD45+ CD31+ subsets of LSECs. FMOs (used for gating), and single antibody staining controls are shown in Additional file. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/33246411/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CD45-Antibody-OX-1-BSA-Free-Flow-Cytometry-NB100-64895-img0006.jpg)
![Flow Cytometry: CD45 Antibody (OX-1) [NB100-64895] - Staining of rat peripheral blood lymphocytes with mouse anti-rat CD45 antibody (OX-1) [NB100-64895].](http://images.novusbio.com/fullsize/CD45-Antibody-OX-1-Flow-Cytometry-NB100-64895-img0001.jpg)
![Immunocytochemistry/Immunofluorescence: CD14 Antibody (M5E2) [NB100-77758] - Representative immunostaining of CD14 (red) in adult human lung tissue sample with nuclei counterstained blue. This image was submitted by customer review. Image from the Alexa Fluor 647 version of this antibody.](http://images.novusbio.com/fullsize/CD14-Antibody-M5E2-Immunocytochemistry-Immunofluorescence-NB100-77758-img0009.jpg "Immunocytochemistry/Immunofluorescence: CD14 Antibody (M5E2) [NB100-77758] - Representative immunostaining of CD14 (red) in adult human lung tissue sample with nuclei counterstained blue. This image was submitted by customer review. Image from the Alexa Fluor 647 version of this antibody.")
![Flow Cytometry: CD14 Antibody (M5E2) [NB100-77758] - A surface stain was performed on human peripheral blood monocytes with CD163 (EDHu-1) antibody NB110-40686APC and a matched isotype control NBP2-27287APC. Cells were incubated in an antibody dilution of 1 ug/mL for 20 minutes at room temperature. A co-stain was performed with NB100-77758AF488.](http://images.novusbio.com/fullsize/CD14-Antibody-M5E2-Flow-Cytometry-NB100-77758-img0007.jpg)
![Immunocytochemistry/Immunofluorescence: CD14 Antibody (M5E2) [NB100-77758] - Human lung tissue was stained with FITC-conjugated CD14 (Green) for overnight. Image from the Alexa Fluor 488 version of this antibody.](http://images.novusbio.com/fullsize/CD14-Antibody-M5E2-Immunocytochemistry-Immunofluorescence-NB100-77758-img0008.jpg)
![Flow Cytometry: CD14 Antibody (M5E2) [NB100-77758] - Human peripheral blood monocytes stained with M5E2 APC](http://images.novusbio.com/fullsize/CD14-Antibody-M5E2-Flow-Cytometry-NB100-77758-img0001.jpg)
![Flow Cytometry: CD14 Antibody (M5E2) [NB100-77758] - Analysis using the FITC conjugate of NB100-77758. Staining of Human peripheral blood monocytes with M5E2 FITC.](http://images.novusbio.com/fullsize/CD14-Antibody-M5E2-Flow-Cytometry-NB100-77758-img0004.jpg)
![Flow Cytometry: CD14 Antibody (M5E2) [NB100-77758] - Analysis using the PE conjugate of NB100-77758. Staining of CD14 in human PBMC using anti-CD14 antibody conjugated with PE. Image from verified customer review.](http://images.novusbio.com/fullsize/CD14-Antibody-M5E2-Flow-Cytometry-NB100-77758-img0005.jpg)
![Flow Cytometry: CD14 Antibody (M5E2) [NB100-77758] - Analysis using PE conjugate of NB100-77758. A cell surface stain was performed on hPBMCs with ILT5 antibody (MM0413-9S32) NBP2-11729 (top image) and a matched isotype control NBP2-27287 (bottom image). Cells were incubated in an antibody dilution of 1:200 for 20 minutes at room temperature. Both antibodies were conjugated to APC. A co-stain was performed using CD14 antibody (M5E2) NB100-77758PE.](http://images.novusbio.com/fullsize/CD14-Antibody-M5E2-Flow-Cytometry-NB100-77758-img0006.jpg)
![Dual RNAscope ISH-IHC: CD14 Antibody (M5E2) [NB100-77758] - TNFA mRNA (red) and CD14 protein (green) were detected in formalin-fixed paraffin-embedded tissue sections of human malignant lymph node. ACD's Integrated Co-Detection Workflow was performed using ACD RNAScope Probe Hs-TNFA and CD14 antibody (M5E2) at 1:200 dilution. Tissue was stained on Leica Bond RX using RNAscope (TM) 2.5 LS Reagent Kit-RED, BOND Polymer Refine Detection (DAB) and Hematoxylin, BOND Polymer Refine Red Detection and Hematoxylin and RNAscope (TM) 2.5 LS Green Accessory Pack. Tissue was counterstained with 50% hematoxylin (blue).](http://images.novusbio.com/fullsize/CD14-Antibody-M5E2-Dual-RNAscope-ISH-IHC-NB100-77758-img0010.jpg)
![In vivo assay: IKK gamma Inhibitor Peptide Set [NBP2-26504] - NBD peptide blocks constitutive NF-kB as shown by EMSA. U266 cells were treated with 100 uM of control or NBD peptide for different time periods. Nuclear extracts were isolated and checked for NF-kB-DNA binding activity.](http://images.novusbio.com/fullsize/IKK-gamma-Inhibitor-Peptide-Set-In-vivo-assay-NBP2-26504-img0010.jpg "In vivo assay: IKK gamma Inhibitor Peptide Set [NBP2-26504] - NBD peptide blocks constitutive NF-kB as shown by EMSA. U266 cells were treated with 100 uM of control or NBD peptide for different time periods. Nuclear extracts were isolated and checked for NF-kB-DNA binding activity.")
![In vivo assay: IKK gamma Inhibitor Peptide Set [NBP2-26504] - NBD peptide blocks constitutive NF-kB activation in human multiple myeloma cells. U266 cells were treated with 100 uM of control (A & B) or NBD peptide (C & D) for 12 hr, cytospun, plated on glass slides, air dried for 1 hr at room temperature and fixed with cold acetone. Slides were blocked with 5% normal goat serum for 1 hr and then incubated with rabbit polyclonal anti-human p65 antibody (A & C) followed by Ig-Alexa 594 second step. In control peptide treated cells, p65 translocates to nucleus (A), whereas NBD peptide prevents translocation of p65 into the nucleus (C). B & D: Nuclear staining with DNA binding dye.](http://images.novusbio.com/fullsize/IKK-gamma-Inhibitor-Peptide-Set-In-vivo-assay-NBP2-26504-img0012.jpg)
![IKK gamma Inhibitor Peptide Set [NBP2-26504] - The IKK complex consists of IKKalpha + IKKbeta+ NEMO. NEMO (IKKgamma/NF-kB Essential MOdulator) is a scaffold protein required for the kinase activity of IKKalpha + IKKbeta. NBD (NEMO Binding Domain) inhibits formation of the IKK complex (IKKalpha + IKKbeta+ NEMO) by binding to NEMO and blocking IKK complex formation. In this regard, NBD is considered to be an 'IKKalpha and IKKBeta decoy' Blocking IKK complex formation suppresses downstream events in the NF-kB signaling pathway that rely on the IKK complex including phosphorylation of IkBalpha, and subsequence IkBalpha ubiquination, degradation and release of NF-kB. Hence, NF-kB is retained in the cytoplasm in its inactive state.](http://images.novusbio.com/fullsize/IKK-gamma-Inhibitor-Peptide-Set-NBP2-26504-img0014.jpg)
![Functional (Inhibition): IKK gamma Inhibitor Peptide Set [NBP2-26504] - TLR5/NF-kB/SEAPorter HEK 293 (NBP2-26277) cells were plated in 96-well plates at 5 x 10^4 cells/well for 16 h. Cells were preincubated with different concentrations (0, 1, 5, 10, 25 and 50 uM) of Inhibitory Peptide (NBP2-26504) and Control Peptide (NBP2-29334) for 1 h. Cells were then stimulated with 1 ng/ml Flagellin (NBP2-25289) for 24 h. Secreted alkaline phosphatase (SEAP) was analyzed using SEAPorter Assay Kit (NBP2-25285). *p < 0.05 versus control peptide at the corresponding concentrations (Mann-Whitney U test).](http://images.novusbio.com/fullsize/IKK-gamma-Inhibitor-Peptide-Set-Functional-Inhibition-NBP2-26504-img0016.jpg)
![Immunocytochemistry/Immunofluorescence: IGF-II R/IGF2R Antibody (2G11) [NB300-514] - HeLa cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-IGF-II R/IGF2R Antibody (2G11) NB300-514 at 1 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/IGF-II-R-IGF2R-Antibody-2G11-Immunocytochemistry-Immunofluorescence-NB300-514-img0014.jpg "Immunocytochemistry/Immunofluorescence: IGF-II R/IGF2R Antibody (2G11) [NB300-514] - HeLa cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-IGF-II R/IGF2R Antibody (2G11) NB300-514 at 1 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.")
![Immunohistochemistry: Mannose 6 Phosphate Receptor (Cation independent) Antibody (2G11) [NB300-514] - Staining of human testis using NB300-514 antibody at 1:100.](http://images.novusbio.com/fullsize/Mannose-6-Phosphate-Receptor-Cation-independent-Antibody-2G11-Immunohistochemistry-NB300-514-img0011.jpg)
![Flow Cytometry: IGF-II R/IGF2R Antibody (2G11) [NB300-514] - An intracellular stain was performed on MCF7 cells with IGF-II R/IGF2R [2G11] Antibody NB300-514AF647 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.](http://images.novusbio.com/fullsize/IGF-II-R-IGF2R-Antibody-2G11-Flow-Cytometry-NB300-514-img0013.jpg)
![Immunocytochemistry/Immunofluorescence: Mannose 6 Phosphate Receptor (Cation independent) Antibody (2G11) [NB300-514] - Mannose 6-Phosphate Receptor staining (green), F-Actin staining with Phalloidin (red) and nuclei with DAPI (blue) is shown. Cells were grown on chamber slides and fixed with formaldehyde prior to staining. Cells were probed without (control) or with or an antibody recognizing Mannose 6-Phosphate Receptor at a dilution of 1:20 over night at 4C, washed with PBS and incubated with a DyLight-488 conjugated.](http://images.novusbio.com/fullsize/Mannose-6-Phosphate-Receptor-Cation-independent-Antibody-2G11-Immunocytochemistry-Immunofluorescence-NB300-514-img0006.jpg)
![Immunocytochemistry/Immunofluorescence: Mannose 6 Phosphate Receptor (Cation independent) Antibody (2G11) [NB300-514] - HMVEC Cells](http://images.novusbio.com/fullsize/Mannose-6-Phosphate-Receptor-Cation-independent-Antibody-2G11-Immunocytochemistry-Immunofluorescence-NB300-514-img0007.jpg)
![Immunocytochemistry/Immunofluorescence: Mannose 6 Phosphate Receptor (Cation independent) Antibody (2G11) [NB300-514] - Staining in Hela Cells. Mannose 6-Phosphate Receptor staining (green), F-Actin staining with Phalloidin (red) and nuclei with DAPI (blue) is shown. Cells were grown on chamber slides and fixed with formaldehyde prior to staining. Cells were probed without (control) or with an antibody recognizing Mannose 6-Phosphate Receptor at a dilution of 1:20 over night at 4 C, washed with PBS and incubated with a DyLight-488 conjugated secondary antibody.](http://images.novusbio.com/fullsize/Mannose-6-Phosphate-Receptor-Cation-independent-Antibody-2G11-Immunocytochemistry-Immunofluorescence-NB300-514-img0008.jpg)
![Immunocytochemistry/Immunofluorescence: IGF-II R/Mannose 6 Phosphate Receptor (Cation independent) Antibody (2G11) [NB300-514] - Mannose 6 Phosphate Receptor (Cation independent) Antibody (2G11) [NB300-514] - Mannose 6 Phosphate Receptor (Cation independent) antibody (2G11) was tested at (1:250) in HeLa cells with Dylight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and DyLight-550 (red).](http://images.novusbio.com/fullsize/Mannose-6-Phosphate-Receptor-Cation-independent-Antibody-2G11-Immunocytochemistry-Immunofluorescence-NB300-514-img0010.jpg)
![Flow Cytometry: Mannose 6 Phosphate Receptor (Cation independent) Antibody (2G11) [NB300-514] - Intracellular flow cytometric staining of 1 x 10^6 MCF-7 cells using Mannose 6 Phosphate Receptor antibody (dark blue). Isotype control shown in orange. An antibody concentration of 1 ug/1x10^6 cells was used.](http://images.novusbio.com/fullsize/Mannose-6-Phosphate-Receptor-Cation-independent-Antibody-2G11-Flow-Cytometry-NB300-514-img0012.jpg)
![Western Blot: PSGL-1/CD162 Antibody (HECA-452) [NB100-78039] - Cutaneous Lymphocyte Antigen (CLA) Antibody (HECA-452) [NB100-78039] - Analysis of human tonsil (1), human spleen (2), and human lymph node (3) tissue using CD162 antibody at a concentration of 2 ug/ml.](http://images.novusbio.com/fullsize/Cutaneous-Lymphocyte-Antigen-CLA-Antibody-HECA-452-Western-Blot-NB100-78039-img0006.jpg "Western Blot: PSGL-1/CD162 Antibody (HECA-452) [NB100-78039] - Cutaneous Lymphocyte Antigen (CLA) Antibody (HECA-452) [NB100-78039] - Analysis of human tonsil (1), human spleen (2), and human lymph node (3) tissue using CD162 antibody at a concentration of 2 ug/ml.")
![Immunohistochemistry-Paraffin: PSGL-1/CD162 Antibody (HECA-452) [NB100-78039] - Human tonsil tissue stained with PSGL-1/CD162 Antibody (HECA-452) at 5ug/mL, and Leica Refine DAB kit. IHC-P image submitted by a verified customer review.](http://images.novusbio.com/fullsize/PSGL-1-CD162-Antibody-HECA-452-Immunohistochemistry-Paraffin-NB100-78039-img0014.jpg)
![Flow (Cell Surface): PSGL-1/CD162 Antibody (HECA-452) [NB100-78039] - Cutaneous Lymphocyte Antigen (CLA) Antibody (HECA-452) [NB100-78039] - A cell surface stain was performed on CD3+ hPBMCs with Cutaneous Lymphocyte Antigen (CLA) antibody (HECA-452) NB100-78039 and a matched isotype control NBP2-31379. Cells were incubated in an antibody dilution of 1 ug/mL for 20 minutes at room temperature, followed by mouse F(ab)2 IgG (H+L) APC-conjugated secondary antibody [F0101B, R&D Systems]. A co-stain was performed using CD3 antibody NBP2-25186APC.](http://images.novusbio.com/fullsize/Cutaneous-Lymphocyte-Antigen-CLA-Antibody-HECA-452-Flow-Cell-Surface-NB100-78039-img0008.jpg)
![Immunohistochemistry-Paraffin: PSGL-1/CD162 Antibody (HECA-452) [NB100-78039] - Cutaneous Lymphocyte Antigen (CLA) Antibody (HECA-452) [NB100-78039] - IHC analysis of formalin-fixed paraffin-embedded tissue section of human breast adenocarcinoma using CLA antibody (clone HECA-452) at 5 ug/ml concentration. The antibody generated a membrane-cytoplasmic staining in the cancerous cells of breast adenocarcinoma. Note:- Besides lymphocytes, CLA has been shown to be present on cells of normal endometrium as well as breast cancer tissues (PMID 19625313 and 22970241).](http://images.novusbio.com/fullsize/Cutaneous-Lymphocyte-Antigen-CLA-Antibody-HECA-452-Immunohistochemistry-Paraffin-NB100-78039-img0004.jpg)
![Flow Cytometry: PSGL-1/CD162 Antibody (HECA-452) [NB100-78039] - Cutaneous Lymphocyte Antigen (CLA) Antibody (HECA-452) [NB100-78039] - Human peripheral blood lymphocytes stained with purified HECA-452, followed by anti-mouse IgG FITC](http://images.novusbio.com/fullsize/Cutaneous-Lymphocyte-Antigen-CLA-Antibody-HECA-452-Flow-Cytometry-NB100-78039-img0005.jpg)
![Flow (Cell Surface): PSGL-1/CD162 Antibody (HECA-452) [NB100-78039] - Cutaneous Lymphocyte Antigen (CLA) Antibody (HECA-452) [NB100-78039] - A cell surface stain was performed on CD14+ hPBMCs with Cutaneous Lymphocyte Antigen (CLA) antibody (HECA-452) NB100-78039 and a matched isotype control NBP2-31379. Cells were incubated in an antibody dilution of 1 ug/mL for 20 minutes at room temperature, followed by rat-Dylight 488 conjugated secondary antibody. A co-stain was performed using CD14 antibody NB100-77758AF488.](http://images.novusbio.com/fullsize/Cutaneous-Lymphocyte-Antigen-CLA-Antibody-HECA-452-Flow-Cell-Surface-NB100-78039-img0007.jpg)
![Western Blot: CD36 Antibody (1283D) [NBP2-54790] - Western blot shows lysates of human placenta tissue and human platelets. PVDF membrane was probed with 1 ug/ml of Rabbit Anti-Human CD36 Monoclonal antibody (catalog number NBP2-54790) followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (catalog number HAF008). A specific band was detected for CD36/SR-B3 at approximately 85 kDa (as indicated). This experiment was conducted under reducing conditions.](http://images.novusbio.com/fullsize/CD36-SR-B3-Antibody-1283D-Western-Blot-NBP2-54790-img0023.jpg "Western Blot: CD36 Antibody (1283D) [NBP2-54790] - Western blot shows lysates of human placenta tissue and human platelets. PVDF membrane was probed with 1 ug/ml of Rabbit Anti-Human CD36 Monoclonal antibody (catalog number NBP2-54790) followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (catalog number HAF008). A specific band was detected for CD36/SR-B3 at approximately 85 kDa (as indicated). This experiment was conducted under reducing conditions.")
![Immunohistochemistry-Paraffin: CD36 Antibody (1283D) [NBP2-54790] - CD36 was detected in immersion fixed paraffin-embedded sections of human heart using Rabbit Anti-Human CD36/SR-B3 Monoclonal Antibody for 1 hour at room temperature followed by incubation with the Anti-Rabbit IgG VisUCyte(TM) HRP Polymer Antibody. Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to cardiomyocyte membranes.](http://images.novusbio.com/fullsize/CD36-SR-B3-Antibody-1283D-Immunohistochemistry-Paraffin-NBP2-54790-img0002.jpg)
![Western Blot: CD36 Antibody (1283D) [NBP2-54790] - Total protein from human skin and adipose tissue was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 1.0 ug/ml anti-CD36 in 1% non-fat milk in TBST and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.](http://images.novusbio.com/fullsize/CD36-SR-B3-Antibody-1283D-Western-Blot-NBP2-54790-img0001.jpg)
![Immunocytochemistry/Immunofluorescence: CD36 Antibody (1283D) [NBP2-54790] - HepG2 cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton-X100. The cells were incubated with anti-CD36 (1283D) at 5.0 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:500 dilution. Alpha tubulin (DM1A) NB100-690 was used as a co-stain at a 1:1000 dilution and detected with an anti-mouse Dylight 550 (Red) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective..](http://images.novusbio.com/fullsize/CD36-SR-B3-Antibody-1283D-Immunocytochemistry-Immunofluorescence-NBP2-54790-img0003.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: CD36 Antibody (1283D) - BSA Free [NBP2-54790] - 3T3-L1 adipocytes were pretreated and treated with ML348 (10 uM) for 1 h, followed by BSA or oleate treatment for another 1 h. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32958780/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CD36-Antibody-1283D-BSA-Free-Western-Blot-NBP2-54790-img0024.jpg)
![Western Blot: CD36 Antibody (1283D) - BSA Free [NBP2-54790] - LYN phosphorylates DHHC5 & is required for the endocytosis of FAs.a 3T3-L1 adipocytes pretreated with serum-free medium for 4 h & PP2 (15 μM) for 1 h, followed by treatment with BSA or oleate (100 μM) for 5 min. Cells harvested & immunoprecipitated with anti-DHHC5 antibody to detect phosphorylation of Tyr91. b 3T3-L1 adipocytes transduced with indicated shRNA set up & treated with oleate for 5 min. Cells harvested to detect Tyr91 phosphorylation as in (a). c On day 0, HEK293T cells set up at 2.5 × 105 cells per 6-cm dish. On day 2, cells transfected with 0.5 μg of WT, Y91E, or Y91F of DHHC5-Flag/pCDH-puro and/or 0.5 μg LYN/pCDNA3.3. On day 3, cells harvested & immunoprecipitated with anti-Flag M2 beads to detect phosphorylation of DHHC5 (pY). Control & LYN knockdown adipocytes pretreated & treated with BSA or oleate (100 μM) for 1 h, followed by immunostaining (d), surface biotinylation (e), & Acyl-RAC (f) assays. Control & CD36 knockdown 3T3-L1 adipocytes pretreated & treated with oleate (100 μM) for indicated time (g) or 5 min (h). Cells harvested & subjected to immunoprecipitation of LYN to detect phosphorylation of LYN (Y396). i, j WT & Cd36−/− SVFs set up & subjected to FA uptake as in Fig. 3h, i, except that cells pretreated with PP2 (15 μM). Each value represents mean ± SEM obtained from 20 cells. Two-sided Student’s t test was performed between DMSO & PP2 treated cells. k WT & Cd36−/− adipocytes set up & subjected to 3H-oleate uptake as in Fig. 3j, except that cells pretreated with PP2 (15 μM). Each value represents mean ± SEM obtained from 3samples. Two-sided Student’s t test was performed between DMSO & PP2 treated cells. These experiments repeated at least twice. Source data provided as a Source Data file. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32958780), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-54790_rabbit-monoclonal-cd36-antibody-1283d-3102024161365.jpg)
![Western Blot: CD36 Antibody (1283D) - BSA Free [NBP2-54790] - LYN phosphorylates DHHC5 & is required for the endocytosis of FAs.a 3T3-L1 adipocytes pretreated with serum-free medium for 4 h & PP2 (15 μM) for 1 h, followed by treatment with BSA or oleate (100 μM) for 5 min. Cells harvested & immunoprecipitated with anti-DHHC5 antibody to detect phosphorylation of Tyr91. b 3T3-L1 adipocytes transduced with indicated shRNA set up & treated with oleate for 5 min. Cells harvested to detect Tyr91 phosphorylation as in (a). c On day 0, HEK293T cells set up at 2.5 × 105 cells per 6-cm dish. On day 2, cells transfected with 0.5 μg of WT, Y91E, or Y91F of DHHC5-Flag/pCDH-puro and/or 0.5 μg LYN/pCDNA3.3. On day 3, cells harvested & immunoprecipitated with anti-Flag M2 beads to detect phosphorylation of DHHC5 (pY). Control & LYN knockdown adipocytes pretreated & treated with BSA or oleate (100 μM) for 1 h, followed by immunostaining (d), surface biotinylation (e), & Acyl-RAC (f) assays. Control & CD36 knockdown 3T3-L1 adipocytes pretreated & treated with oleate (100 μM) for indicated time (g) or 5 min (h). Cells harvested & subjected to immunoprecipitation of LYN to detect phosphorylation of LYN (Y396). i, j WT & Cd36−/− SVFs set up & subjected to FA uptake as in Fig. 3h, i, except that cells pretreated with PP2 (15 μM). Each value represents mean ± SEM obtained from 20 cells. Two-sided Student’s t test was performed between DMSO & PP2 treated cells. k WT & Cd36−/− adipocytes set up & subjected to 3H-oleate uptake as in Fig. 3j, except that cells pretreated with PP2 (15 μM). Each value represents mean ± SEM obtained from 3samples. Two-sided Student’s t test was performed between DMSO & PP2 treated cells. These experiments repeated at least twice. Source data provided as a Source Data file. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32958780), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-54790_rabbit-monoclonal-cd36-antibody-1283d-310202416114783.jpg)
![Western Blot: CD36 Antibody (1283D) - BSA Free [NBP2-54790] - FAs trigger internalization of CD36.a, b On day 8 of differentiation, 3T3-L1 adipocytes were pretreated with serum-free medium for 4 h, & then treated with BSA-conjugated oleate (100 μM) for indicated time. a One set of cells was subjected to immunostaining with anti-CD36 & anti-CAV1 antibodies. LipidTOX was used to label lipid droplets. Images were taken under a Zeiss LSM-780 microscope in a 3D Z-stack mode & reconstructed using Imaris 9.2.0. b The other set of cells was subjected to surface biotinylation assay & blotted with indicated antibodies. c, d On day 4 of differentiation, 3T3-L1 cells were infected with lentivirus encoding scrambled shRNA or shRNAs against CD36 or CAV1. On day 5, cells were selected with 5 μg/ml puromycin. On day 8, cells were pretreated as in (a) & treated with oleate (100 μM) for 4 h, followed by immunostaining with anti-CD36 & anti-CAV1 antibodies (c), or surface biotinylation assay (d). e, f 3T3-L1 adipocytes were pretreated as in (a) & treated with BSA-conjugated FAs with different chain lengths or saturation (100 μM) for 4 h. Cells were subjected to immunostaining with anti-CD36 antibody (e), or surface biotinylation assay (f). After oleate treatment for 4 h, 3T3-L1 adipocytes were switched to serum-free medium for indicated time & harvested for immunostaining (g) & surface biotinylation (h). The scale bars were as indicated in each figure. These experiments were repeated at least three times. Source data are provided as a Source Data file. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32958780), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-54790_rabbit-monoclonal-cd36-antibody-1283d-310202416121990.jpg)
![Western Blot: CD36 Antibody (1283D) - BSA Free [NBP2-54790] - FAs trigger internalization of CD36.a, b On day 8 of differentiation, 3T3-L1 adipocytes were pretreated with serum-free medium for 4 h, & then treated with BSA-conjugated oleate (100 μM) for indicated time. a One set of cells was subjected to immunostaining with anti-CD36 & anti-CAV1 antibodies. LipidTOX was used to label lipid droplets. Images were taken under a Zeiss LSM-780 microscope in a 3D Z-stack mode & reconstructed using Imaris 9.2.0. b The other set of cells was subjected to surface biotinylation assay & blotted with indicated antibodies. c, d On day 4 of differentiation, 3T3-L1 cells were infected with lentivirus encoding scrambled shRNA or shRNAs against CD36 or CAV1. On day 5, cells were selected with 5 μg/ml puromycin. On day 8, cells were pretreated as in (a) & treated with oleate (100 μM) for 4 h, followed by immunostaining with anti-CD36 & anti-CAV1 antibodies (c), or surface biotinylation assay (d). e, f 3T3-L1 adipocytes were pretreated as in (a) & treated with BSA-conjugated FAs with different chain lengths or saturation (100 μM) for 4 h. Cells were subjected to immunostaining with anti-CD36 antibody (e), or surface biotinylation assay (f). After oleate treatment for 4 h, 3T3-L1 adipocytes were switched to serum-free medium for indicated time & harvested for immunostaining (g) & surface biotinylation (h). The scale bars were as indicated in each figure. These experiments were repeated at least three times. Source data are provided as a Source Data file. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32958780), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-54790_rabbit-monoclonal-cd36-antibody-1283d-31020241612242.jpg)
![Western Blot: CD36 Antibody (1283D) - BSA Free [NBP2-54790] - FAs trigger internalization of CD36.a, b On day 8 of differentiation, 3T3-L1 adipocytes were pretreated with serum-free medium for 4 h, & then treated with BSA-conjugated oleate (100 μM) for indicated time. a One set of cells was subjected to immunostaining with anti-CD36 & anti-CAV1 antibodies. LipidTOX was used to label lipid droplets. Images were taken under a Zeiss LSM-780 microscope in a 3D Z-stack mode & reconstructed using Imaris 9.2.0. b The other set of cells was subjected to surface biotinylation assay & blotted with indicated antibodies. c, d On day 4 of differentiation, 3T3-L1 cells were infected with lentivirus encoding scrambled shRNA or shRNAs against CD36 or CAV1. On day 5, cells were selected with 5 μg/ml puromycin. On day 8, cells were pretreated as in (a) & treated with oleate (100 μM) for 4 h, followed by immunostaining with anti-CD36 & anti-CAV1 antibodies (c), or surface biotinylation assay (d). e, f 3T3-L1 adipocytes were pretreated as in (a) & treated with BSA-conjugated FAs with different chain lengths or saturation (100 μM) for 4 h. Cells were subjected to immunostaining with anti-CD36 antibody (e), or surface biotinylation assay (f). After oleate treatment for 4 h, 3T3-L1 adipocytes were switched to serum-free medium for indicated time & harvested for immunostaining (g) & surface biotinylation (h). The scale bars were as indicated in each figure. These experiments were repeated at least three times. Source data are provided as a Source Data file. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32958780), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-54790_rabbit-monoclonal-cd36-antibody-1283d-310202416114740.jpg)
![Western Blot: CD36 Antibody (1283D) - BSA Free [NBP2-54790] - FAs trigger internalization of CD36.a, b On day 8 of differentiation, 3T3-L1 adipocytes were pretreated with serum-free medium for 4 h, & then treated with BSA-conjugated oleate (100 μM) for indicated time. a One set of cells was subjected to immunostaining with anti-CD36 & anti-CAV1 antibodies. LipidTOX was used to label lipid droplets. Images were taken under a Zeiss LSM-780 microscope in a 3D Z-stack mode & reconstructed using Imaris 9.2.0. b The other set of cells was subjected to surface biotinylation assay & blotted with indicated antibodies. c, d On day 4 of differentiation, 3T3-L1 cells were infected with lentivirus encoding scrambled shRNA or shRNAs against CD36 or CAV1. On day 5, cells were selected with 5 μg/ml puromycin. On day 8, cells were pretreated as in (a) & treated with oleate (100 μM) for 4 h, followed by immunostaining with anti-CD36 & anti-CAV1 antibodies (c), or surface biotinylation assay (d). e, f 3T3-L1 adipocytes were pretreated as in (a) & treated with BSA-conjugated FAs with different chain lengths or saturation (100 μM) for 4 h. Cells were subjected to immunostaining with anti-CD36 antibody (e), or surface biotinylation assay (f). After oleate treatment for 4 h, 3T3-L1 adipocytes were switched to serum-free medium for indicated time & harvested for immunostaining (g) & surface biotinylation (h). The scale bars were as indicated in each figure. These experiments were repeated at least three times. Source data are provided as a Source Data file. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32958780), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-54790_rabbit-monoclonal-cd36-antibody-1283d-310202416114741.jpg)
![Western Blot: CD36 Antibody (1283D) - BSA Free [NBP2-54790] - CD36-mediated caveolar endocytosis transports FAs into cells.a–c 3T3-L1 adipocytes were pretreated with serum-free medium for 4 h, & then treated with BSA-conjugated PacFA (50 μM) for 20 min, followed by UV crosslinking on ice for 30 min. a, b Cells were subjected to click chemistry using an N3-Alexa Fluro 488, & immunostained with anti-CD36 antibody. Colocalization of PacFA & CD36 was quantified from 24 cells over three independent experiments & plotted in (b). The value represents mean ± SEM. c Cells were lysed & subjected to click chemistry assay using N3-biotin. PacFA-labeled proteins were captured with streptavidin beads & subjected to western blot using anti-CD36 & anti-FABP4 antibodies. d WT, Cav1−/−, Cd36−/−, & Cav1−/−;Cd36−/− SVFs were isolated & differentiated into adipocytes & treated with 100 μM 3H-oleate (specific activity, 2268 dpm/nmol) for 1 h. Lipid fractions were extracted from the cells & subjected to scintillation counting. The radioactive counting was normalized to protein content. Each value represents mean ± SEM obtained from three samples. Two-sided Student’s t test was performed between WT & each of the knockout cells. These experiments were repeated twice. Source data are provided as a Source Data file. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32958780), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-54790_rabbit-monoclonal-cd36-antibody-1283d-310202416113520.jpg)
![Western Blot: IL-1 beta/IL-1F2 Antibody [NBP1-19775] - Analysis of IL1 beta Antibody in extracts from HeLa cells.](http://images.novusbio.com/fullsize/IL-1-beta-IL-1F2-Antibody-Western-Blot-NBP1-19775-img0004.jpg "Western Blot: IL-1 beta/IL-1F2 Antibody [NBP1-19775] - Analysis of IL1 beta Antibody in extracts from HeLa cells.")
![Immunohistochemistry: IL-1 beta/IL-1F2 Antibody - BSA Free [NBP1-19775] - In situ expression of IL-6 in glomerular and tubulointerstitial compartments in patients with diabetic nephropathy DN (right) and control group (left). Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32723296/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/IL-1-beta-IL-1F2-Antibody---BSA-Free-Immunohistochemistry-NBP1-19775-img0006.jpg)
![Immunohistochemistry: IL-1 beta/IL-1F2 Antibody [NBP1-19775] - Staining in the cytoplasm of villi and in the crypt cells of human lung carcinoma tissue.](http://images.novusbio.com/fullsize/IL-1-beta-IL-1F2-Antibody-Immunohistochemistry-NBP1-19775-img0005.jpg)
![Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - A) Kidney from control did not show any specific staining in the glomeruli. Only erythrocytes (arrow) showed weak fluorescence. B) 1 day: endothelium & material within the capillaries of a glomerulus were highly fluorescent (white arrow). In an adjacent glomerulus, only the endothelium was stained (white arrowhead) not for the lumina of the vessels (black arrow). C) Erythrocytes (arrowhead) and endothelium (arrow). D) 7 days: fluorescence within the capillaries (arrowhead) & endothelium was weaker. E) 1 day after ranibizumab injection, the endothelium cell layer (white arrow) and erythrocytes (arrowhead and black arrow) were fluorescent. F) The fluorescence (arrowhead) was nearly lost 7 days after injection. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0113701) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Goat-anti-Human-IgG-Fc-fragment-Secondary-Antibody-Immunohistochemistry-NB7446-img0002.jpg "Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - A) Kidney from control did not show any specific staining in the glomeruli. Only erythrocytes (arrow) showed weak fluorescence. B) 1 day: endothelium & material within the capillaries of a glomerulus were highly fluorescent (white arrow). In an adjacent glomerulus, only the endothelium was stained (white arrowhead) not for the lumina of the vessels (black arrow). C) Erythrocytes (arrowhead) and endothelium (arrow). D) 7 days: fluorescence within the capillaries (arrowhead) & endothelium was weaker. E) 1 day after ranibizumab injection, the endothelium cell layer (white arrow) and erythrocytes (arrowhead and black arrow) were fluorescent. F) The fluorescence (arrowhead) was nearly lost 7 days after injection. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0113701) licensed under a CC-BY license.")
![Western Blot: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - Image from verified customer review. Image using the HRP form of this antibody.](http://images.novusbio.com/fullsize/Goat-anti-Human-IgG-Fc-Secondary-Antibody-Western-Blot-NB7446-img0001.jpg)
![Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - Immune fluorescent photomicrographs of glomeruli from control (A), aflibercept-treated (B–D) & ranibizumab-treated (E–F) monkeys eyes.In all figures, the asterisks label the spaces of the Bowman capsule. A) Kidney sections from the control animal did not show any specific staining with anti-human IgG-Fc antibody in the glomeruli. Only the erythrocytes (arrow) within the capillaries showed a weak fluorescence. B) One day after aflibercept injection, the endothelium cell layer & material within the capillaries of a glomerulus were highly fluorescent (white arrow) after labelling with an antibody against the Fc region of IgG. In an adjacent glomerulus, only the endothelium was stained (white arrowhead) whereas the lumina of the vessels did not contain IgG-Fc positive material (black arrow). C) Erythrocytes within the glomeruli (arrowhead) as well as the endothelium (arrow) were highly fluorescent. D) Seven days after aflibercept injection, the fluorescent material within the capillaries (arrowhead) & the fluorescence intensity of the endothelium became weaker. E) One day after ranibizumab injection, the endothelium cell layer (white arrow) & erythrocytes (arrowhead & black arrow in the inset) were fluorescent after staining with an antibody against human Fab of IgG. F) The specific fluorescence of the endothelium (arrow) & erythrocytes (arrowhead) was nearly lost seven days after injection of ranibizumab. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25415380), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb7446_goat-polyclonal-goat-anti-human-igg-fc-secondary-antibody-310202416154644.jpg)
![Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - Immune fluorescent photomicrographs of glomeruli from control (A), aflibercept-treated (B–D) & ranibizumab-treated (E–F) monkeys eyes.In all figures, the asterisks label the spaces of the Bowman capsule. A) Kidney sections from the control animal did not show any specific staining with anti-human IgG-Fc antibody in the glomeruli. Only the erythrocytes (arrow) within the capillaries showed a weak fluorescence. B) One day after aflibercept injection, the endothelium cell layer & material within the capillaries of a glomerulus were highly fluorescent (white arrow) after labelling with an antibody against the Fc region of IgG. In an adjacent glomerulus, only the endothelium was stained (white arrowhead) whereas the lumina of the vessels did not contain IgG-Fc positive material (black arrow). C) Erythrocytes within the glomeruli (arrowhead) as well as the endothelium (arrow) were highly fluorescent. D) Seven days after aflibercept injection, the fluorescent material within the capillaries (arrowhead) & the fluorescence intensity of the endothelium became weaker. E) One day after ranibizumab injection, the endothelium cell layer (white arrow) & erythrocytes (arrowhead & black arrow in the inset) were fluorescent after staining with an antibody against human Fab of IgG. F) The specific fluorescence of the endothelium (arrow) & erythrocytes (arrowhead) was nearly lost seven days after injection of ranibizumab. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25415380), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb7446_goat-polyclonal-goat-anti-human-igg-fc-secondary-antibody-310202416165644.jpg)
![Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - Immune fluorescent photomicrographs of glomeruli from control (A), aflibercept-treated (B–D) & ranibizumab-treated (E–F) monkeys eyes.In all figures, the asterisks label the spaces of the Bowman capsule. A) Kidney sections from the control animal did not show any specific staining with anti-human IgG-Fc antibody in the glomeruli. Only the erythrocytes (arrow) within the capillaries showed a weak fluorescence. B) One day after aflibercept injection, the endothelium cell layer & material within the capillaries of a glomerulus were highly fluorescent (white arrow) after labelling with an antibody against the Fc region of IgG. In an adjacent glomerulus, only the endothelium was stained (white arrowhead) whereas the lumina of the vessels did not contain IgG-Fc positive material (black arrow). C) Erythrocytes within the glomeruli (arrowhead) as well as the endothelium (arrow) were highly fluorescent. D) Seven days after aflibercept injection, the fluorescent material within the capillaries (arrowhead) & the fluorescence intensity of the endothelium became weaker. E) One day after ranibizumab injection, the endothelium cell layer (white arrow) & erythrocytes (arrowhead & black arrow in the inset) were fluorescent after staining with an antibody against human Fab of IgG. F) The specific fluorescence of the endothelium (arrow) & erythrocytes (arrowhead) was nearly lost seven days after injection of ranibizumab. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25415380), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb7446_goat-polyclonal-goat-anti-human-igg-fc-secondary-antibody-310202416154630.jpg)
![Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - Immune fluorescent photomicrographs of glomeruli from control (A), aflibercept-treated (B–D) & ranibizumab-treated (E–F) monkeys eyes.In all figures, the asterisks label the spaces of the Bowman capsule. A) Kidney sections from the control animal did not show any specific staining with anti-human IgG-Fc antibody in the glomeruli. Only the erythrocytes (arrow) within the capillaries showed a weak fluorescence. B) One day after aflibercept injection, the endothelium cell layer & material within the capillaries of a glomerulus were highly fluorescent (white arrow) after labelling with an antibody against the Fc region of IgG. In an adjacent glomerulus, only the endothelium was stained (white arrowhead) whereas the lumina of the vessels did not contain IgG-Fc positive material (black arrow). C) Erythrocytes within the glomeruli (arrowhead) as well as the endothelium (arrow) were highly fluorescent. D) Seven days after aflibercept injection, the fluorescent material within the capillaries (arrowhead) & the fluorescence intensity of the endothelium became weaker. E) One day after ranibizumab injection, the endothelium cell layer (white arrow) & erythrocytes (arrowhead & black arrow in the inset) were fluorescent after staining with an antibody against human Fab of IgG. F) The specific fluorescence of the endothelium (arrow) & erythrocytes (arrowhead) was nearly lost seven days after injection of ranibizumab. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25415380), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb7446_goat-polyclonal-goat-anti-human-igg-fc-secondary-antibody-310202416175295.jpg)
![Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - Immune fluorescent photomicrographs of glomeruli from control (A), aflibercept-treated (B–D) & ranibizumab-treated (E–F) monkeys eyes.In all figures, the asterisks label the spaces of the Bowman capsule. A) Kidney sections from the control animal did not show any specific staining with anti-human IgG-Fc antibody in the glomeruli. Only the erythrocytes (arrow) within the capillaries showed a weak fluorescence. B) One day after aflibercept injection, the endothelium cell layer & material within the capillaries of a glomerulus were highly fluorescent (white arrow) after labelling with an antibody against the Fc region of IgG. In an adjacent glomerulus, only the endothelium was stained (white arrowhead) whereas the lumina of the vessels did not contain IgG-Fc positive material (black arrow). C) Erythrocytes within the glomeruli (arrowhead) as well as the endothelium (arrow) were highly fluorescent. D) Seven days after aflibercept injection, the fluorescent material within the capillaries (arrowhead) & the fluorescence intensity of the endothelium became weaker. E) One day after ranibizumab injection, the endothelium cell layer (white arrow) & erythrocytes (arrowhead & black arrow in the inset) were fluorescent after staining with an antibody against human Fab of IgG. F) The specific fluorescence of the endothelium (arrow) & erythrocytes (arrowhead) was nearly lost seven days after injection of ranibizumab. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25415380), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb7446_goat-polyclonal-goat-anti-human-igg-fc-secondary-antibody-310202416163732.jpg)
![Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - Immune fluorescent photomicrographs of glomeruli from control (A), aflibercept-treated (B–D) & ranibizumab-treated (E–F) monkeys eyes.In all figures, the asterisks label the spaces of the Bowman capsule. A) Kidney sections from the control animal did not show any specific staining with anti-human IgG-Fc antibody in the glomeruli. Only the erythrocytes (arrow) within the capillaries showed a weak fluorescence. B) One day after aflibercept injection, the endothelium cell layer & material within the capillaries of a glomerulus were highly fluorescent (white arrow) after labelling with an antibody against the Fc region of IgG. In an adjacent glomerulus, only the endothelium was stained (white arrowhead) whereas the lumina of the vessels did not contain IgG-Fc positive material (black arrow). C) Erythrocytes within the glomeruli (arrowhead) as well as the endothelium (arrow) were highly fluorescent. D) Seven days after aflibercept injection, the fluorescent material within the capillaries (arrowhead) & the fluorescence intensity of the endothelium became weaker. E) One day after ranibizumab injection, the endothelium cell layer (white arrow) & erythrocytes (arrowhead & black arrow in the inset) were fluorescent after staining with an antibody against human Fab of IgG. F) The specific fluorescence of the endothelium (arrow) & erythrocytes (arrowhead) was nearly lost seven days after injection of ranibizumab. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25415380), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb7446_goat-polyclonal-goat-anti-human-igg-fc-secondary-antibody-310202416171447.jpg)
![Flow Cytometry: MHC Class II Antibody (M5/114.15.2) [NBP1-43312] - Analysis using the PE conjugate of NBP1-43312. Analysis of mouse splenocyte suspensions using MHC Class II PE and can be used at less than or equal to 0.125 ug per test. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test.](http://images.novusbio.com/fullsize/MHC-Class-II-Antibody-M5-114-15-2-Flow-Cytometry-NBP1-43312-img0009.jpg "Flow Cytometry: MHC Class II Antibody (M5/114.15.2) [NBP1-43312] - Analysis using the PE conjugate of NBP1-43312. Analysis of mouse splenocyte suspensions using MHC Class II PE and can be used at less than or equal to 0.125 ug per test. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test.")
![Flow Cytometry: MHC Class II Antibody (M5/114.15.2) [NBP1-43312] - Staining of C57BL/6 splenocytes with 0.06 ug of Rat IgG2b K Isotype Control Purified (cat. NBP1-43323) (open histogram) or 0.06 ug of Anti-Mouse MHC Class II (I-A/I-E) Purified (filled histogram) followed by Anti-Rat IgG FITC (cat. NBP1-69751). Total viable cells were used for analysis.](http://images.novusbio.com/fullsize/MHC-Class-II-Antibody-M5-114-15-2-Flow-Cytometry-NBP1-43312-img0001.jpg)
![Flow Cytometry: MHC Class II Antibody (M5/114.15.2) [NBP1-43312] - Analysis using the Allophycocyanin conjugate of NBP1-43312. Staining of C57BL/6 splenocytes with Anti-Mouse CD3e FITC and 0.015 micrograms of Rat IgG2b ? Isotype Control APC (left) or 0.015 micrograms of Anti-Mouse MHC Class II (I-A/I-E) APC (right).](http://images.novusbio.com/fullsize/MHC-Class-II-Antibody-M5-114-15-2-Flow-Cytometry-NBP1-43312-img0006.jpg)
![Flow Cytometry: MHC Class II Antibody (M5/114.15.2) [NBP1-43312] - Analysis using the Biotin conjugate of NBP1-43312. Staining of C57BL/6 splenocytes with 0.015 ug of Rat IgG2b K Isotype Control Biotin (open histogram) or 0.015 ug of Anti-Mouse MHC Class II (I-A/I-E) Biotin followed by Streptavidin PE (filled histogram).](http://images.novusbio.com/fullsize/MHC-Class-II-Antibody-M5-114-15-2-Flow-Cytometry-NBP1-43312-img0007.jpg)
![Flow Cytometry: MHC Class II Antibody (M5/114.15.2) [NBP1-43312] - Analysis using the FITC conjugate of NBP1-43312. Staining of C57BL/6 splenocytes with Anti-Mouse CD3e and 0.06 micrograms of Rat IgG2b k Isotype Control FITC (left) or 0.06 micrograms of Anti-Mouse MHC Class II (I-A/I-E) FITC (right). Cells in the lymphocyte gate were used for analysis.](http://images.novusbio.com/fullsize/MHC-Class-II-Antibody-M5-114-15-2-Flow-Cytometry-NBP1-43312-img0008.jpg)
![Western Blot: nNOS Antibody [NBP1-39681] - Effects of ER alpha and ER beta Antagonists on NE Regulation of VMN nNOS Protein Expression. Micropunch-dissected VMN tissue was obtained from groups of ovariectomized, estradiol-replaced female rats pretreated by intra-VMN delivery of MPP, PHTPP, or vehicle (Veh) prior to NE administration for Western blot analysis of neuronal nitric oxide synthase (nNOS) - Panel 2A,F(5, 12)=12.67,p<.0001 - protein expression. Data depict mean normalized protein optical density (O.D.) values+/-SEMfor groups of rats (n=6 per group) infused with Veh (white bars) or NE (gray bars) after delivery of Veh (solid bars), MPP (diagonal-striped bars), or PHTPP (cross-hatched bars) administration. *p<.05; **p<.01; ***p<.001. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32233668/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/nNOS-Antibody-Western-Blot-NBP1-39681-img0007.jpg "Western Blot: nNOS Antibody [NBP1-39681] - Effects of ER alpha and ER beta Antagonists on NE Regulation of VMN nNOS Protein Expression. Micropunch-dissected VMN tissue was obtained from groups of ovariectomized, estradiol-replaced female rats pretreated by intra-VMN delivery of MPP, PHTPP, or vehicle (Veh) prior to NE administration for Western blot analysis of neuronal nitric oxide synthase (nNOS) - Panel 2A,F(5, 12)=12.67,p<.0001 - protein expression. Data depict mean normalized protein optical density (O.D.) values+/-SEMfor groups of rats (n=6 per group) infused with Veh (white bars) or NE (gray bars) after delivery of Veh (solid bars), MPP (diagonal-striped bars), or PHTPP (cross-hatched bars) administration. *p<.05; **p<.01; ***p<.001. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32233668/) licensed under a CC-BY license.")
![Immunohistochemistry-Paraffin: nNOS Antibody [NBP1-39681] - Analysis of anti-nNOS / NOS1 antibody with human brain, cerebellum at concentration 5 ug/ml.](http://images.novusbio.com/fullsize/nNOS-Antibody-Immunohistochemistry-Paraffin-NBP1-39681-img0004.jpg)
![Western Blot: nNOS Antibody [NBP1-39681]](http://images.novusbio.com/fullsize/nNOS-Antibody-Western-Blot-NBP1-39681-img0006.jpg)
![Immunohistochemistry-Paraffin: nNOS Antibody [NBP1-39681] - Analysis of anti-nNOS / NOS1 antibody with human brain, cortex at concentration 5 ug/ml.](http://images.novusbio.com/fullsize/nNOS-Antibody-Immunohistochemistry-Paraffin-NBP1-39681-img0003.jpg)
![Western Blot: nNOS Antibody [NBP1-39681] - Laser-Catapult Microdissection of Immunolabeled ventromedial hypothalamic nucleus (VMN) GABA or Nitrergic Neurons: Western Blot Confirmation of Accuracy of Immunocytochemical Identification of Neurotransmitter Phenotype. VMN neurons were identified in situ for glutamate decarboxylase65/67 (GAD65/67)- (top row, Panel 1A) or neuronal nitric oxide (nNOS)-immunoreactivity (-ir) (bottom row, Panel 2A); representative GAD65/67- or nNOS-ir-positive neurons are indicated by blue arrows. Areas shown in Panels 1A & 2A were rephotographed after positioning of a continuous laser track (depicted in green) around a single GAD65/67-ir (Panel 1B, blue arrow) or nNOS-ir neuron (Panel 2B, blue arrow) & subsequent ejection of the encircled cell by laser pulse (Panels 1C & 2C). Note that this microdissection technique causes negligible destruction of surrounding tissue & minimal inclusion of adjacent tissue. Western blot analysis of triplicate cell lysate pools produced from immunolabeled GAD65/67 (Panel 1D) or nNOS (Panel 2D) neurons from Veh/Veh animals showed that these proteins are expressed in VMN neuron samples obtained by combinatory immunocytochemistry/laser-catapult microdissection. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32233668), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-39681_rabbit-nnos-pab-310202416154636.jpg)
![Western Blot: nNOS Antibody [NBP1-39681] - Effects of ER alpha & ER beta Antagonists on NE Regulation of VMN GAD & nNOS Protein Expression. Micropunch-dissected VMN tissue was obtained from groups of ovariectomized, estradiol-replaced female rats pretreated by intra-VMN delivery of MPP, PHTPP, or vehicle (Veh) prior to NE administration for Western blot analysis of neuronal nitric oxide synthase (nNOS)—Panel 2A, F(5, 12) = 12.67, p < .0001—or glutamate decarboxylase65/67 (GAD)—Panel 2B, F(5, 12) = 7.13, p = .0003—protein expression. Data depict mean normalized protein optical density (O.D.) values ± SEM for groups of rats (n = 6 per group) infused with Veh (white bars) or NE (gray bars) after delivery of Veh (solid bars), MPP (diagonal-striped bars), or PHTPP (cross-hatched bars) administration. *p < .05; **p < .01; ***p < .001. MPP = 1,3-Bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride; PHTPP = 4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol; NE = norepinephrine. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32233668), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-39681_rabbit-nnos-pab-310202416175279.jpg)
![Western Blot: TDP-43/TARDBP Antibody [NB110-55376] - Total protein from HeLa, MCF7 and mouse brain was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 1.0 ug/ml anti-TARDBP in 1% block buffer and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.](http://images.novusbio.com/fullsize/TDP-43-TARDBP-Antibody-Western-Blot-NB110-55376-img0012.jpg "Western Blot: TDP-43/TARDBP Antibody [NB110-55376] - Total protein from HeLa, MCF7 and mouse brain was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 1.0 ug/ml anti-TARDBP in 1% block buffer and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.")
![Immunocytochemistry/Immunofluorescence: TDP-43/TARDBP Antibody [NB110-55376] - HeLa cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.5% Triton X-100 in PBS for 5 minutes. The cells were incubated with TDP-43/TARDBP Antibody conjugated to Alexa Fluor 488 (NB110-55376AF488) at 10 ug/ml for 1 hour at room temperature. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/TDP-43-TARDBP-Antibody-Immunocytochemistry-Immunofluorescence-NB110-55376-img0014.jpg)
![Immunocytochemistry/Immunofluorescence: TDP-43/TARDBP Antibody [NB110-55376] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.5% Triton X-100. The cells were incubated with anti-TARDBP at 2 ug/ml overnight at 4C and detected with an anti-rabbit DyLight 488 (Green) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/TDP-43-TARDBP-Antibody-Immunocytochemistry-Immunofluorescence-NB110-55376-img0011.jpg)
![Immunohistochemistry-Paraffin: TDP-43/TARDBP Antibody [NB110-55376] - Analysis of FFPE human placenta using TDP-43 antibody at 1:250 on a Bond Rx autostainer (Leica Biosystems). The assay involved 20 minutes of heat induced antigen retrieval (HIER) using 10mM sodium citrate buffer (pH 6.0) and endogenous peroxidase quenching with peroxide block. The sections were incubated with primary antibody for 30 minutes and Bond Polymer Refine Detection (Leica Biosystems) with DAB was used for signal development followed by counterstaining with hematoxylin. Whole slide scanning and capturing of representative images was performed using Aperio AT2 (Leica Biosystems). Nuclear staining was observed. Staining was performed by Histowiz.](http://images.novusbio.com/fullsize/TDP-43-TARDBP-Antibody-Immunohistochemistry-Paraffin-NB110-55376-img0010.jpg)
![Western Blot: TDP-43/TARDBP Antibody [NB110-55376] - TARDBP antibody was tested in HeLa WCE.](http://images.novusbio.com/fullsize/TDP-43-TARDBP-Antibody-Western-Blot-NB110-55376-img0004.jpg)
![Western Blot: TDP-43/TARDBP Antibody [NB110-55376] - Cells were transfected with the pCMV6-ENTRY control or pCMV6-ENTRY TARDBP cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-TARDBP.](http://images.novusbio.com/fullsize/TDP-43-TARDBP-Antibody-Western-Blot-NB110-55376-img0006.jpg)
![Immunocytochemistry/Immunofluorescence: TDP-43/TARDBP Antibody [NB110-55376] - TARDBP antibody was tested in MCF-7 cells with DyLight 488 (Green). Nuclei and alpha-tubulin were counterstained with DAPI (Blue) and DyLight 550 (Red).](http://images.novusbio.com/fullsize/TDP-43-TARDBP-Antibody-Immunocytochemistry-Immunofluorescence-NB110-55376-img0001.jpg)
![Immunocytochemistry/Immunofluorescence: TDP-43/TARDBP Antibody [NB110-55376] - Analysis using the DyLight 550 conjugate of NB110-55376. Staining of Human iPS derived neurons, fixed in 4% formaldehyde solution. NB110-55376R was diluted 1:200. All antibodies were diluted in PBS/BSA 3% (w/v) ) Triton X-100 0,3 % (v/v). Images taken by an Arrayscan (Cellomics). Blue dots in TDP staining is Hoechst.](http://images.novusbio.com/fullsize/TDP-43-TARDBP-Antibody-Immunocytochemistry-Immunofluorescence-NB110-55376-img0008.jpg)
![Immunocytochemistry/Immunofluorescence: TDP-43/TARDBP Antibody [NB110-55376] - Subcellular distribution of TDP-43 and CWC22 in control DRG sensory neurons. TDP-43 was stained diffusely in the nucleus, excluding SMN foci in sensory neurons. Scale bar: 10 um. Image collected and cropped by CiteAb from the following publication (//dmm.biologists.org/lookup/doi/10.1242/dmm.028225) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TDP-43-TARDBP-Antibody-Immunocytochemistry-Immunofluorescence-NB110-55376-img0013.jpg)
